🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Regeneron Pharmaceuticals Inc (REGN)

NASDAQ
Currency in USD
812.95
-8.05(-0.98%)
Real-time Data
REGN Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
810.22823.56
52 wk Range
784.961,211.20
Prev. Close
821
Open
815.45
Day's Range
810.22-823.56
52 wk Range
784.96-1,211.2
Volume
200,402
Average Volume (3m)
645,056
1-Year Change
3.05%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
REGN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
1,089.43
Upside
+33.57%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Regeneron Pharma Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

InvestingPro Research for Regeneron Pharmaceuticals Inc


Eylea's Crossroads
Explore Regeneron's strategy to maintain Eylea's market dominance amidst biosimilar competition and the transition to Eylea HD formulation
Dupixent's Ascendancy
Discover how Dupixent's expansion into COPD and other indications is driving Regeneron's growth, with analysts projecting significant revenue potential
Pipeline Potential
Delve into Regeneron's diverse pipeline, including promising oncology and obesity programs, and their potential to shape the company's future
Financial Outlook
Analyst price targets for Regeneron range from $1015 to $1300, reflecting optimism about the company's growth prospects and pipeline developments
Read full SWOT analysis

Compare REGN to Peers and Sector

Metrics to compare
REGN
Peers
Sector
Relationship
P/E Ratio
18.8x−1.3x−0.7x
PEG Ratio
1.24−0.030.00
Price/Book
3.0x0.3x2.6x
Price / LTM Sales
6.3x2.2x3.2x
Upside (Analyst Target)
37.1%471.7%45.2%
Fair Value Upside
Unlock44.7%7.0%Unlock

People Also Watch

307.49
CDNS
+3.26%
166.63
BIIB
-0.98%
563.13
SNPS
+1.75%
493.84
VRTX
+0.78%
382.24
ULTA
+0.65%

FAQ

What Is the Regeneron Pharma (REGN) Stock Price Today?

The Regeneron Pharma stock price today is 812.95

What Stock Exchange Does Regeneron Pharma Trade On?

Regeneron Pharma is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Regeneron Pharma?

The stock symbol for Regeneron Pharma is "REGN."

What Is the Regeneron Pharma Market Cap?

As of today, Regeneron Pharma market cap is 87.42B.

What is Regeneron Pharma Earnings Per Share?

The Regeneron Pharma EPS is 43.26.

What Is the Next Regeneron Pharma Earnings Date?

Regeneron Pharma will release its next earnings report on 31 Jan 2025.

From a Technical Analysis Perspective, Is REGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.